|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
DK1392359T4
(da)
|
2001-05-11 |
2013-06-10 |
Ludwig Inst For Cancer Res Ltd |
Specifikke bindingsproteiner og deres anvendelser.
|
|
US7742064B2
(en)
*
|
2001-10-30 |
2010-06-22 |
Semiconductor Energy Laboratory Co., Ltd |
Signal line driver circuit, light emitting device and driving method thereof
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
US7811572B2
(en)
|
2005-08-24 |
2010-10-12 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
|
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
|
|
CA3014224C
(en)
|
2009-02-05 |
2022-05-24 |
Immunogen, Inc. |
Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
|
|
JP5784592B2
(ja)
|
2009-06-03 |
2015-09-24 |
イミュノジェン・インコーポレーテッド |
抱合方法
|
|
FR2949469A1
(fr)
*
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
|
CN105777907B
(zh)
|
2010-02-24 |
2020-03-17 |
伊缪诺金公司 |
叶酸受体1抗体与免疫缀合物以及其用途
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
MX368648B
(es)
|
2010-04-15 |
2019-10-09 |
Seattle Genetics Inc |
Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
|
|
CN103068405A
(zh)
|
2010-04-15 |
2013-04-24 |
西雅图基因公司 |
靶向吡咯并苯并二氮杂卓结合物
|
|
FR2963007B1
(fr)
*
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
|
PL3153504T3
(pl)
|
2010-12-09 |
2019-04-30 |
Immunogen Inc |
Sposoby otrzymywania naładowanych środków sieciujących
|
|
SI2675480T1
(sl)
|
2011-02-15 |
2019-05-31 |
Immunogen, Inc. |
Metode priprave konjugatov
|
|
AU2015202826B2
(en)
*
|
2011-02-15 |
2017-03-30 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
|
EA033468B1
(ru)
|
2011-03-29 |
2019-10-31 |
Immunogen Inc |
Способы получения конъюгата "антитело-майтансиноид"
|
|
EP2524929A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sanofi |
Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
|
|
EP2717916B1
(en)
|
2011-06-10 |
2017-03-08 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US9399641B2
(en)
|
2011-09-20 |
2016-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
|
|
JP6104257B2
(ja)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
|
CA2850264C
(en)
|
2011-10-14 |
2019-11-05 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
|
AU2012322934B2
(en)
|
2011-10-14 |
2016-09-08 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
CA2850375C
(en)
|
2011-10-14 |
2019-07-02 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
CN104093425A
(zh)
*
|
2011-12-13 |
2014-10-08 |
伊缪诺金公司 |
N-羟基琥珀酰亚胺用于改善缀合物的稳定性的用途
|
|
CN104822656B
(zh)
|
2012-05-15 |
2018-05-01 |
西雅图基因公司 |
自稳定接头偶联物
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
|
HK1211208A1
(zh)
|
2012-08-22 |
2016-05-20 |
Immunogen, Inc. |
細胞毒性苯並二氮呯衍生物
|
|
EP2904089A4
(en)
|
2012-10-04 |
2016-05-25 |
Immunogen Inc |
USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
|
|
EP2906297B1
(en)
*
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
DK2839860T3
(da)
|
2012-10-12 |
2019-06-17 |
Medimmune Ltd |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
PT2906253T
(pt)
|
2012-10-12 |
2018-11-05 |
Medimmune Ltd |
Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
|
|
EP2906249B1
(en)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
|
BR112015008238A2
(pt)
|
2012-10-12 |
2017-11-28 |
Adc Therapeutics Sarl |
conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
|
|
KR101995620B1
(ko)
|
2012-10-12 |
2019-07-03 |
에이디씨 테라퓨틱스 에스에이 |
피롤로벤조디아제핀-항체 컨주게이트
|
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
PT2906248T
(pt)
|
2012-10-12 |
2019-03-04 |
Medimmune Ltd |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
DK2906298T3
(en)
*
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
AU2013366493B2
(en)
|
2012-12-21 |
2017-08-24 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US9567340B2
(en)
|
2012-12-21 |
2017-02-14 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
DK2968494T3
(en)
|
2013-03-13 |
2019-03-04 |
Seattle Genetics Inc |
ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs
|
|
HK1220698A1
(zh)
*
|
2013-03-13 |
2017-05-12 |
Seattle Genetics, Inc. |
环糊精和抗体药物偶联物制剂
|
|
MX363787B
(es)
|
2013-03-13 |
2019-04-03 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de los mismos.
|
|
KR102066318B1
(ko)
|
2013-03-13 |
2020-01-14 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨쥬게이트
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
|
US10233249B2
(en)
|
2013-03-19 |
2019-03-19 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
BR112016002829A2
(pt)
|
2013-08-12 |
2017-09-19 |
Genentech Inc |
Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2927022C
(en)
|
2013-10-11 |
2018-08-21 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
|
WO2015054659A1
(en)
|
2013-10-11 |
2015-04-16 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
PT3057585T
(pt)
|
2013-10-15 |
2020-10-21 |
Seagen Inc |
Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
|
|
AR098743A1
(es)
|
2013-12-13 |
2016-06-08 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33
|
|
JP6980384B2
(ja)
|
2013-12-16 |
2021-12-15 |
ジェネンテック， インコーポレイテッド |
１−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
|
|
EP3572425A1
(en)
*
|
2013-12-17 |
2019-11-27 |
AIMM Therapeutics B.V. |
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
|
|
MX2016010295A
(es)
|
2014-02-11 |
2016-10-17 |
Seattle Genetics Inc |
Reduccion selectiva de proteinas.
|
|
JP6417421B2
(ja)
|
2014-02-28 |
2018-11-07 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
荷電連結体及び共役体のためのその使用
|
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック， インコーポレイテッド |
抗ｇｐｃ３抗体及びイムノコンジュゲート
|
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
|
CR20170111A
(es)
*
|
2014-09-03 |
2017-05-23 |
Immunogen Inc |
Derivados de benzodiazepina citotóxicos
|
|
EP3189057A1
(en)
|
2014-09-03 |
2017-07-12 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
|
JP2017531620A
(ja)
|
2014-09-12 |
2017-10-26 |
ジェネンテック， インコーポレイテッド |
システイン操作抗体及びコンジュゲート
|
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗－ｂ７－ｈ４抗體及免疫結合物
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
JP2017533887A
(ja)
|
2014-09-17 |
2017-11-16 |
ジェネンテック， インコーポレイテッド |
ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
|
|
CA2957148A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
|
TW201632531A
(zh)
|
2015-01-14 |
2016-09-16 |
必治妥美雅史谷比公司 |
苯二氮呯二聚物，其結合物及製造與使用方法
|
|
US9504694B2
(en)
*
|
2015-03-19 |
2016-11-29 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
EA039619B1
(ru)
*
|
2015-05-20 |
2022-02-17 |
Иммуноджен, Инк. |
Способ получения индолинобензодиазепиновых соединений
|
|
GB201510010D0
(en)
|
2015-06-09 |
2015-07-22 |
King S College London |
PDD and BPD compounds
|
|
EP3307749A4
(en)
|
2015-06-15 |
2019-06-19 |
Hangzhou Dac Biotech Co., Ltd |
HYDROPHILIC LINKER FOR CONJUGATION
|
|
AU2016284340A1
(en)
|
2015-06-23 |
2018-02-08 |
Bristol-Myers Squibb Company |
Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
|
|
SI3313845T1
(sl)
*
|
2015-06-29 |
2021-01-29 |
Immunogen, Inc. |
Konjugati spremenjenih protiteles cisteina
|
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3778602B1
(en)
*
|
2015-07-21 |
2023-07-12 |
ImmunoGen, Inc. |
Methods of preparing cytotoxic benzodiazepine derivatives
|
|
US20180339985A1
(en)
|
2015-08-21 |
2018-11-29 |
Femtogenix Limited |
Pdd compounds
|
|
GB201514928D0
(en)
*
|
2015-08-21 |
2015-10-07 |
King S College London |
PDD compounds
|
|
EP4477269A3
(en)
|
2015-09-20 |
2025-03-19 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
|
|
CR20180243A
(es)
|
2015-10-02 |
2018-07-31 |
Genentech Inc |
Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
RS65120B1
(sr)
|
2015-11-25 |
2024-02-29 |
Immunogen Inc |
Farmaceutske formulacije i postupci za njihovu upotrebu
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
US11229708B2
(en)
|
2015-12-04 |
2022-01-25 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
FR3049605B1
(fr)
*
|
2016-04-05 |
2018-03-23 |
Arkema France |
Procede d'obtention de films fins et articles filmogenes
|
|
EP3454864A4
(en)
|
2016-04-21 |
2021-01-13 |
Abbvie Stemcentrx LLC |
Novel anti-bmpr1b antibodies and methods of use
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
WO2017201132A2
(en)
|
2016-05-18 |
2017-11-23 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
US10526294B2
(en)
|
2016-06-24 |
2020-01-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
|
KR20240010534A
(ko)
|
2016-08-09 |
2024-01-23 |
씨젠 인크. |
개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
|
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
CN110049780A
(zh)
|
2016-10-10 |
2019-07-23 |
塞勒兰特治疗公司 |
异喹啉并苯并二氮杂卓(iqb)-1(氯甲基)-2,3-二氢-1h-苯并[e]吲哚(cbi)二聚体
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
AU2017355402A1
(en)
*
|
2016-11-02 |
2019-05-30 |
Health Research, Inc. |
Combination treatment with antibody-drug conjugates and PARP inhibitors
|
|
KR20220147719A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
CA3036983A1
(en)
|
2016-11-21 |
2018-05-24 |
Cureab Gmbh |
Anti-gp73 antibodies and immunoconjugates
|
|
EP3544983A2
(en)
|
2016-11-23 |
2019-10-02 |
Immunogen, Inc. |
Selective sulfonation of benzodiazepine derivatives
|
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
|
EP3559038B1
(en)
|
2016-12-21 |
2022-12-14 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
|
MD3558391T2
(ro)
|
2016-12-23 |
2022-05-31 |
Immunogen Inc |
Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora
|
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Ｍｅｔ抗體以及其免疫結合物及用途
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
RS61795B1
(sr)
|
2017-02-08 |
2021-06-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin antitela
|
|
JP7527787B2
(ja)
|
2017-03-24 |
2024-08-05 |
シージェン インコーポレイテッド |
グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
|
|
SMT202200490T1
(it)
|
2017-04-18 |
2023-01-13 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
EP3612533A1
(en)
*
|
2017-04-20 |
2020-02-26 |
Immunogen, Inc. |
Methods of preparing indolinobenzodiazepine derivatives
|
|
JP7175917B2
(ja)
*
|
2017-04-27 |
2022-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
新規のａｌｋ２阻害剤及びｂｍｐシグナル伝達の阻害方法
|
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
|
KR102442736B1
(ko)
|
2017-06-14 |
2022-09-16 |
에이디씨 테라퓨틱스 에스에이 |
항-cd19 adc의 투여를 위한 투약량 체제
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
SI3668874T1
(sl)
|
2017-08-18 |
2022-04-29 |
Medimmune Limited |
Pirolobenzodiazepinski konjugati
|
|
CA3177215C
(en)
|
2017-09-29 |
2026-06-09 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
WO2019133652A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Immunogen, Inc. |
Benzodiazepine derivatives
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN112166115A
(zh)
*
|
2018-05-29 |
2021-01-01 |
尹图赛利有限公司 |
新型苯二氮杂*衍生物及其用途
|
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
|
|
CA3106544A1
(en)
|
2018-08-08 |
2020-02-13 |
Mitchell Ho |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
EP3873912B1
(en)
|
2018-10-31 |
2026-03-25 |
Intocell, Inc. |
Fused heterocyclic benzodiazepine derivatives and uses thereof
|
|
CN113302207B
(zh)
|
2018-11-16 |
2025-05-13 |
维尔托索宾科公司 |
Cd38和icam1抗体及其用途
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
AU2020206308B2
(en)
|
2019-01-08 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
KR20210124308A
(ko)
|
2019-01-30 |
2021-10-14 |
트루바인딩 아이엔씨. |
항-gal3 항체 및 이의 용도
|
|
CN113631560B
(zh)
|
2019-03-15 |
2025-02-18 |
麦迪穆有限责任公司 |
氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
|
|
US20230094471A1
(en)
*
|
2019-03-29 |
2023-03-30 |
Immunogen, Inc. |
Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
|
|
AU2020289360A1
(en)
*
|
2019-06-04 |
2022-01-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating autoimmune diseases
|
|
CA3156761A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
CN115279789A
(zh)
|
2019-12-06 |
2022-11-01 |
真和制药有限公司 |
破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
|
|
EP4041769A1
(en)
|
2019-12-12 |
2022-08-17 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
KR102927945B1
(ko)
|
2020-03-27 |
2026-02-23 |
어비디티 바이오사이언시스 인크. |
근이영양증의 치료용 조성물 및 방법
|
|
AU2021251875A1
(en)
|
2020-04-10 |
2022-11-03 |
Seagen Inc. |
Charge variant linkers
|
|
US12508262B2
(en)
|
2020-04-30 |
2025-12-30 |
Keros Therapeutics, Inc. |
Methods of using ALK2 inhibitors
|
|
MX2022014786A
(es)
|
2020-05-26 |
2023-01-16 |
Truebinding Inc |
Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
|
|
CN111646999A
(zh)
*
|
2020-07-30 |
2020-09-11 |
内江师范学院 |
一种吲哚啉羧酸类化合物及其制备方法
|
|
WO2022082058A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Eleusis Therapeutics Us, Inc. |
Method of treatment by tryptamine alkaloids
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
WO2022098812A1
(en)
|
2020-11-04 |
2022-05-12 |
Keros Therapeutics, Inc. |
Methods of treating iron overload
|
|
JP2024510435A
(ja)
|
2021-03-18 |
2024-03-07 |
シージェン インコーポレイテッド |
生体活性化合物の内部移行複合体からの選択的薬物放出
|
|
IL305886A
(en)
|
2021-03-18 |
2023-11-01 |
Seagen Inc |
Selective release of drugs from internalized conjugates of biologically active compounds
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
JP2024526764A
(ja)
|
2021-07-13 |
2024-07-19 |
トゥルーバインディング，インコーポレイテッド |
タンパク質凝集を防止する方法
|
|
EP4384502A1
(en)
|
2021-08-13 |
2024-06-19 |
ImmunoGen, Inc. |
Improved methods for preparing cytotoxic benzodiazepine derivatives
|
|
EP4401792A4
(en)
|
2021-09-16 |
2025-12-03 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
US20230279120A1
(en)
|
2021-11-09 |
2023-09-07 |
Truebinding, Inc. |
Methods of treating or inhibiting cardiovascular diseases
|
|
PE20242350A1
(es)
|
2022-05-03 |
2024-12-16 |
Genentech Inc |
Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
|
|
AU2023298568A1
(en)
|
2022-06-30 |
2025-01-09 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
WO2024258995A2
(en)
*
|
2023-06-13 |
2024-12-19 |
Delix Therapeutics, Inc. |
Fused tetrahydroazepine psychoplastogens and uses thereof
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
AU2025218272A1
(en)
|
2024-02-07 |
2026-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2026165109A1
(en)
|
2025-01-28 |
2026-08-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tem8 monoclonal antibodies and their use
|